Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy.
Humans
Pancreatic Neoplasms
/ drug therapy
Male
Female
Middle Aged
Deoxycytidine
/ analogs & derivatives
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Angiography, Digital Subtraction
Adenocarcinoma
/ drug therapy
Infusions, Intra-Arterial
Adult
Prospective Studies
Oxaliplatin
/ administration & dosage
Gemcitabine
Infusions, Intravenous
Pancreas
/ pathology
Organoplatinum Compounds
GEMOX
Intravenous chemotherapy
Pancreatic arterial infusion
Pancreatic head and neck tumors
Unresectable pancreatic cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
07
09
2023
accepted:
24
07
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
Advanced pancreatic adenocarcinoma lacks effective treatment options, and systemic gemcitabine-based chemotherapy offers only marginal survival benefits at the cost of significant toxicities and adverse events. New therapeutic options with better drug availability are warranted. This study aims to evaluate the safety and efficacy of digital subtraction angiography (DSA)-guided pancreatic arterial infusion (PAI) versus intravenous chemotherapy (IVC) using the gemcitabine and oxaliplatin (GEMOX) regimen in unresectable locally advanced or metastatic pancreatic cancer (PC) patients. This study prospectively enrolled 51 eligible treatment-naive patients with unresectable PC to receive GEMOX treatment via PAI or IVC (1:1 ratio randomization) from December 2015 to December 2019. Cycles were repeated monthly, and each process consisted of two treatments administered bi-weekly. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), 1-year survival, 6-month survival, tumor-site subgroup survival, and incidences of adverse events were compared. The median OS of the PAI and IVC groups were 9.93 months and 10.07 months, respectively (p = 0.3049). The median PFS of the PAI and IVC groups were 5.07 months and 4.23 months (p = 0.1088). No significant differences were found in the ORR (11.54% vs. 4%, p = 0.6312), DCR (53.85% vs. 44%, p = 0.482), and 1-year OS rate (44% vs. 20.92%, p = 0.27) in PAI and IVC groups. The 6-month OS rate was significantly higher in the PAI group (100%) than in the IVC group (83.67%) (p = 0.0173). The median OS of patients in PAI group with pancreatic head and neck tumors were significantly higher than those of body and tail tumors (12.867 months vs. 9 months, p = 0.0214). The incidences of hematologic disorders, liver function disorders, and digestive disorders in the IVC group were higher than in the PAI group (p < 0.05). GEMOX PAI therapy presented a higher 6-month OS rate and fewer adverse events than IVC in advanced pancreatic adenocarcinoma patients. Those with pancreatic head and neck tumors may yield a superior treatment outcome from PAI treatment. NCT02635971. 21/12/2015.
Sections du résumé
BACKGROUND
BACKGROUND
Advanced pancreatic adenocarcinoma lacks effective treatment options, and systemic gemcitabine-based chemotherapy offers only marginal survival benefits at the cost of significant toxicities and adverse events. New therapeutic options with better drug availability are warranted. This study aims to evaluate the safety and efficacy of digital subtraction angiography (DSA)-guided pancreatic arterial infusion (PAI) versus intravenous chemotherapy (IVC) using the gemcitabine and oxaliplatin (GEMOX) regimen in unresectable locally advanced or metastatic pancreatic cancer (PC) patients.
MATERIALS AND METHODS
METHODS
This study prospectively enrolled 51 eligible treatment-naive patients with unresectable PC to receive GEMOX treatment via PAI or IVC (1:1 ratio randomization) from December 2015 to December 2019. Cycles were repeated monthly, and each process consisted of two treatments administered bi-weekly. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), 1-year survival, 6-month survival, tumor-site subgroup survival, and incidences of adverse events were compared.
RESULTS
RESULTS
The median OS of the PAI and IVC groups were 9.93 months and 10.07 months, respectively (p = 0.3049). The median PFS of the PAI and IVC groups were 5.07 months and 4.23 months (p = 0.1088). No significant differences were found in the ORR (11.54% vs. 4%, p = 0.6312), DCR (53.85% vs. 44%, p = 0.482), and 1-year OS rate (44% vs. 20.92%, p = 0.27) in PAI and IVC groups. The 6-month OS rate was significantly higher in the PAI group (100%) than in the IVC group (83.67%) (p = 0.0173). The median OS of patients in PAI group with pancreatic head and neck tumors were significantly higher than those of body and tail tumors (12.867 months vs. 9 months, p = 0.0214). The incidences of hematologic disorders, liver function disorders, and digestive disorders in the IVC group were higher than in the PAI group (p < 0.05).
CONCLUSION
CONCLUSIONS
GEMOX PAI therapy presented a higher 6-month OS rate and fewer adverse events than IVC in advanced pancreatic adenocarcinoma patients. Those with pancreatic head and neck tumors may yield a superior treatment outcome from PAI treatment.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT02635971.
DATE OF REGISTRATION
UNASSIGNED
21/12/2015.
Identifiants
pubmed: 39095759
doi: 10.1186/s12885-024-12695-8
pii: 10.1186/s12885-024-12695-8
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Oxaliplatin
04ZR38536J
Gemcitabine
0
Organoplatinum Compounds
0
Banques de données
ClinicalTrials.gov
['NCT02635971']
Types de publication
Journal Article
Clinical Trial, Phase II
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
941Subventions
Organisme : National Natural Science Foundation of China
ID : Grant No. 82074204
Organisme : Clinical research funding of Fudan University Shanghai Cancer Center
ID : Grant No. YJLC201504
Informations de copyright
© 2024. The Author(s).
Références
Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic arterial infusion of Chemotherapy for Advanced Hepatobiliary cancers: state of the art. Cancers (Basel) 2021, 13(12).
Ranieri G, Laface C. Loco-Regional and systemic chemotherapies for Hepato-pancreatic tumors: Integrated treatments. Cancers (Basel) 2020, 12(10).
Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol. 2011;80(1):40–53.
doi: 10.1016/j.critrevonc.2010.10.005
pubmed: 21067940
Ranieri G, Laforgia M, Nardulli P, Ferraiuolo S, Molinari P, Marech I, Gadaleta CD. Oxaliplatin-based intra-arterial chemotherapy in Colo-rectal Cancer Liver metastases: a review from Pharmacology to Clinical Application. Cancers (Basel) 2019, 11(2).
Gadaleta CD, Solbiati L, Mattioli V, Rubini G, Fazio V, Goffredo V, Vinciarelli G, Gadaleta-Caldarola G, Canniello E, Armenise F, et al. Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients. Radiology. 2013;267(2):627–37.
doi: 10.1148/radiol.12120198
pubmed: 23249572
Datta J, Narayan RR, Kemeny NE, D’Angelica MI. Role of Hepatic Artery Infusion Chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg. 2019;154(8):768–76.
doi: 10.1001/jamasurg.2019.1694
pubmed: 31188415
Lewandowski RJ, Geschwind J-F, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641–57.
doi: 10.1148/radiol.11081489
pubmed: 21602502
pmcid: 3400295
Patt YZ, Mavligit GM, Chuang VP, Wallace S, Johnston S, Benjamin RS, Valdivieso M, Hersh EM. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver. Cancer. 1980;46(2):261–5.
doi: 10.1002/1097-0142(19800715)46:2<261::AID-CNCR2820460207>3.0.CO;2-0
pubmed: 6446376
Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer. 1981;47(2):402–9.
doi: 10.1002/1097-0142(19810115)47:2<402::AID-CNCR2820470231>3.0.CO;2-B
pubmed: 6257376
Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Comparison of arterial infusion Chemotherapy and Chemoembolization for locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. J Gastrointest Surg. 2022;26(11):2292–300.
doi: 10.1007/s11605-022-05421-x
pubmed: 35920966
Gadaleta CD, Catino A, Ranieri G, Armenise F, Console G, Mattioli V. Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall. J Exp Clin Cancer Res. 2003;22(4 Suppl):203–6.
pubmed: 16767932
Ishida H, Makino T, Kobayashi M, Tsuneoka K. Laparoscopic measurement of pancreatic blood flow. Endoscopy. 1983;15(3):107–10.
doi: 10.1055/s-2007-1021480
pubmed: 6223807
Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
doi: 10.1016/S0140-6736(16)00141-0
pubmed: 26830752
Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci 2019, 20(18).
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncology: Official J Am Soc Clin Oncol. 1997;15(6):2403–13.
doi: 10.1200/JCO.1997.15.6.2403
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2005;23(15):3509–16.
doi: 10.1200/JCO.2005.06.023
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O’Dwyer P, Haller D, Catalano P, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncology: Official J Am Soc Clin Oncol. 2009;27(23):3778–85.
doi: 10.1200/JCO.2008.20.9007
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, Iwahashi M, Uchiyama K. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 2002;25(4):366–72.
doi: 10.1097/00006676-200211000-00008
pubmed: 12409831
Ibukuro K. Vascular anatomy of the pancreas and clinical applications. Int J Gastrointest Cancer 2001, 30(1–2).
Xu H-B, Zhang Y-J, Wei W-J, Li W-M, Tu X-Q. Pancreatic tumor: DSA diagnosis and treatment. World J Gastroenterol. 1998;4(1):80–1.
doi: 10.3748/wjg.v4.i1.80
pubmed: 11819240
pmcid: 4767774
Laface C, Laforgia M, Molinari P, Foti C, Ambrogio F, Gadaleta CD, Ranieri G. Intra-arterial infusion Chemotherapy in Advanced Pancreatic Cancer: a Comprehensive Review. Cancers (Basel) 2022, 14(2).
Ishikawa T. Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer? World J Gastroenterol. 2007;13(32):4306–9.
doi: 10.3748/wjg.v13.i32.4306
pubmed: 17708601
pmcid: 4250854
Clark VL, Kruse JA. Arterial catheterization. Crit Care Clin. 1992;8(4):687–97.
doi: 10.1016/S0749-0704(18)30219-7
pubmed: 1327430
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncology: Official J Am Soc Clin Oncol. 2002;20(6):1512–8.
doi: 10.1200/JCO.2002.20.6.1512
Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Annals Oncology: Official J Eur Soc Med Oncol. 2003;14(4):580–5.
doi: 10.1093/annonc/mdg170
Baize N, Abu Shalaa A, Berthier F, Demarquay J-F, Bernard J-L, Rahili A, Piche T, Huet P-M, Tran A, Caroli-Bosc F-X. Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. Gastroenterol Clin Biol. 2005;29(10):1006–9.
doi: 10.1016/S0399-8320(05)88174-6
pubmed: 16435507
Chen Y, Wang X-L, Wang J-H, Yan Z-P, Cheng J-M, Gong G-Q, Liu L-X, Li G-P, Li C-Y. Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer. Anticancer Drugs. 2014;25(8):958–63.
doi: 10.1097/CAD.0000000000000120
pubmed: 24800885
Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Kanemitsu K, Baba H. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol. 2007;30(5):912–21.
doi: 10.1007/s00270-007-9134-2
pubmed: 17710478
Homma H, Akiyama T, Mezawa S, Doi T, Takanashi K, Machida T, Murakami K, Katsuki S, Sato T, Hirata K. Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy. Int J Clin Oncol. 2004;9(3):197–201.
doi: 10.1007/s10147-004-0388-2
pubmed: 15221606
Han S, Cao C, Yuan Y, Chen J, Yin L, Xu H, Liu J, Wang W, Li Y, Wang L, et al. Transcatheter arterial infusion combined with Radioactive particles in the treatment of Advanced Body/Tail pancreatic Cancer: a retrospective cohort study. Pancreas. 2021;50(6):822–6.
doi: 10.1097/MPA.0000000000001851
pubmed: 34347726
Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, Abbas J, Habbal MZ, Malaeb LA, Bikhazi AB. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet. 2005;44(9):957–67.
doi: 10.2165/00003088-200544090-00005
pubmed: 16122282
Aigner KR, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study. Hepatogastroenterology. 1998;45(22):1125–9.
pubmed: 9756018
Han GH, Yin ZX, Meng XJ, He CY, Zhang HB, Sun AH, Wu KC, Ding J, Fan DM. Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma. Chin J Dig Dis. 2006;7(1):45–8.
doi: 10.1111/j.1443-9573.2006.00243.x
pubmed: 16412037
Hong G, Zhou J, Luo J, Xu L, Chen Y, Jiang R. A clinical study on continuous transarterial infusion chemotherapy and systemic venous chemotherapy with gemcitabine and 5-fluorouracil in treating patients with advanced pancreatic carcinoma. Chinese-German J Clin Oncol. 2007;6(5):457–60.
doi: 10.1007/s10330-007-0086-4
Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H, Hao J. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2012;7(7):e40847.
doi: 10.1371/journal.pone.0040847
pubmed: 22815840
pmcid: 3399885
Meyer F, Grote R, Lippert H, Ridwelski K. Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma. Langenbeck’s Archives Surg. 2004;389(1):32–9.
doi: 10.1007/s00423-003-0431-1
Gao S, Zhang P-J, Guo J-H, Chen H, Xu H-F, Liu P, Yang R-J, Zhu X. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol. 2015;21(36):10443–52.
doi: 10.3748/wjg.v21.i36.10443
pubmed: 26420971
pmcid: 4579891
Tempero M, Plunkett W, Van Ruiz V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2003;21(18):3402–8.
doi: 10.1200/JCO.2003.09.140
Tajima H, Kitagawa H, Tsukada T, Okamoto K, Nakanuma S-I, Sakai S, Makino I, Furukawa H, Hayashi H, Oyama K, et al. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Mol Clin Oncol. 2013;1(5):869–74.
doi: 10.3892/mco.2013.152
pubmed: 24649263
pmcid: 3916203
Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, et al. Hepatic artery infusion of Floxuridine in Combination with systemic chemotherapy for pancreatic Cancer Liver Metastasis: a propensity score-matched analysis in two centers. Front Oncol. 2021;11:652426.
doi: 10.3389/fonc.2021.652426
pubmed: 33996572
pmcid: 8113695
Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, et al. Pancreatic adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):202–10.
doi: 10.6004/jnccn.2019.0014
pubmed: 30865919
Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013;71(4):955–63.
doi: 10.1007/s00280-013-2088-y
pubmed: 23377373
pmcid: 3977741
Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang Y-P, Naing A, Janku F, Hou M-M, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016;77(2):357–64.
doi: 10.1007/s00280-015-2946-x
pubmed: 26698868